Eli Lilly announced positive one-year Phase 3 results for Omvoh (mirikizumab-mrkz) in children aged 6 to 17 with moderately to severely active ulcerative colitis. In the SHINE-2 study, 81% of patients responded at 12 weeks, and 50% of responders achieved clinical remission at one year, with half remaining corticosteroid-free without surgery. These results mark Omvoh as the first IL-23p19 inhibitor to show sustained efficacy in pediatric UC, addressing a significant unmet need. Lilly plans to submit these data to regulators to expand Omvoh's label for pediatric use, potentially providing a new treatment option for young patients with this challenging condition.
Eli Lilly's shares are trading at USD 1,241.75 on Pluang, down 1.22% as of Oct 19, 2026 15:51 WIB. The stock has a market cap of $1.12 trillion and a dividend yield of 0.55%, reflecting its strong position in the health sector.
Eli Lilly announced new clinical data presentations at the 2026 European Society for Medical Oncology (ESMO) Congress, featuring updates on several investigational and approved cancer therapies. Key highlights include Phase 1 data for sofetabart mipi...
Eli Lilly transformed from a traditional insulin maker into a pharmaceutical giant, driven by its obesity drug Tirzepatide, sold as Mounjaro and Zepbound. These drugs generated $14.9 billion in Q2 2026 alone, capturing 60% of U.S. obesity prescriptio...
The obesity treatment landscape is rapidly evolving with over 200 companies developing more than 200 pipeline drugs, including late-stage and early-stage clinical trials. Major pharmaceutical firms like Novo Nordisk and Eli Lilly are leading with inn...
Eli Lilly will announce its third-quarter 2026 financial results on October 29, 2026, followed by a conference call at 10 a.m. Eastern time to discuss the company's performance. The call will be accessible via a live webcast on Lilly's investor websi...
New data from Eli Lilly reveal that Omvoh (mirikizumab-mrkz) effectively achieves comprehensive disease control in ulcerative colitis and corticosteroid-free deep remission in Crohn's disease after one year of treatment. These outcomes, observed even...
